Portfolio

OMass Therapeutics

CEO Ros Deegan

OMass Therapeutics is a biotechnology company developing small molecule therapeutics against highly validated target ecosystems.

Its proprietary OdyssION™ drug discovery platform combines next-generation native mass spectrometry, novel biochemistry techniques and custom chemistry to interrogate drug targets within their native ecosystems, providing cell-system fidelity with cell-free precision.

OMass’ lead program, OMS1620, is a best-in-class MC2 (melanocortin-2) receptor antagonist for congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing’s syndrome, designed to maintain efficacy in the presence of elevated ACTH levels. OMass is also advancing a broader preclinical pipeline including an SLC15A4 inhibitor for lupus and other indications related to interferon overproduction and pathogenic B-cell activation.

Headquartered in Oxford, UK, OMass was founded as a spin-out of the University of Oxford to translate pioneering native mass spectrometry research into novel small molecule therapeutics against historically challenging targets and is backed by a top-tier international investor syndicate.

Human Health

Building 4000, Chancellor Court

John Smith Drive

ARC Oxford, OX4 2GX, UK

omass.com

Industry

Biotech

Year Invested

2026

Status

Current

Location

Oxford, UK

OMS1620 has the potential to be a best-in-class treatment for congenital adrenal hyperplasia (CAH), a lifelong genetic disorder in which patients must balance the effects of excess androgens against the long-term harms of high-dose steroids. OMS1620 has been designed to maintain MC2 receptor blockade even at the very high ACTH levels seen in CAH patients. We believe this approach can differentiate OMS1620 from approved therapies and other agents in development, enabling more patients to achieve the ultimate treatment goal of androgen normalization while on physiologic doses of glucocorticoids. We greatly value Forbion's support and guidance as we advance through clinical development."

Ros Deegan

CEO of OMass Therapeutics